The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
CTLA-4 Gene Polymorphism at Position 49 in Exon 1 Reduces the Inhibitory Function of CTLA-4 and Contributes to the Pathogenesis of Graves’ Disease
Open accessAbstract
Activation of T cells requires at least two signals transduced by the Ag-specific TCR and a costimulatory ligand such as CD28. CTLA-4, expressed on activated T cells, binds to B7 present on APCs and functions as a negative regulator of T cell activation. Our laboratory previously reported the association of Graves’ disease (GD) with a specific CTLA-4 gene polymorphism. In theory, reduced expression or function of CTLA-4 might augment autoimmunity. In the present study, we categorized autoimmune thyroid disease patients and normal controls (NC) by genotyping a CTLA-4 exon 1 polymorphism and investigated the function of CTLA-4 in all subjects. PBMCs and DNA were prepared from GD (n = 45), Hashimoto’s thyroiditis (HT) (n = 18), and NC (n = 43). There were more GD patients with the G/G or A/G alleles (82.2% vs 65.1% in NC), and significantly fewer patients with the A/A allele (17.8% vs 34.9% in NC). In the presence of soluble blocking anti-human CTLA-4 mAb, T cell proliferation following incubation with allogeneic EBV-transformed B cells was augmented in a dose-dependent manner. Augmentation induced by CTLA-4 mAb was similar in GD and NC (GD, HT, NC = 156%, 164%, 175%, respectively). We related CTLA-4 polymorphism to mAb augmentation of T cell proliferation in each subgroup (GD, HT, NC). Although PBMC from individuals with the G/G alleles showed 132% augmentation, those with the A/A alleles showed 193% augmentation (p = 0.019). CTLA-4 polymorphism affects the inhibitory function of CTLA-4. The G allele is associated with reduced control of T cell proliferation and thus contributes to the pathogenesis of GD and presumably of other autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Nistico, L. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.7.1075 · Cited by 809
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasetti, C., & Damle, N. K. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1595 · Cited by 581
CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population
Yanagawa, T. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.1.41 · Cited by 465
Harper, K., Balzano, C., Rouvier, E., Mattéi, M. G., Luciani, M. F., & Golstein, P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.3.1037 · Cited by 432
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419
CTLA4 Alanine-17 Confers Genetic Susceptibility to Graves’ Disease and to Type 1 Diabetes Mellitus1
Donner, H., Rau, H., Walfish, P. G., Braun, J., Siegmund, T., Finke, R., Herwig, J., Usadel, K. H., & Badenhoop, K. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3699 · Cited by 396
Regulation of surface and intracellular expression of CTLA4 on mouse T cells
Alegre, M. L., Noel, P. J., Eisfelder, B. J., Chuang, E., Clark, M. R., Reiner, S. L., & Thompson, C. B. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4762 · Cited by 338 · cited 2×
“CD3 plus anti-CD28 mAbs (5) or PMA plus ionomycin (40)).”
BackgroundMethodA CTLA‐4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism
Kotsa, K., Watson, P. F., & Weetman, A. P. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1710996.x · Cited by 258
Wolf, E., Spencer, K. M., & Cudworth, A. G. (1983) · Diabetologia · doi:10.1007/bf00282704 · Cited by 248
Donner, H., Braun, J., Seidl, C., Rau, H., Finke, R., Ventz, M., Walfish, P. G., Usadel, K. H., & Badenhoop, K. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4406 · Cited by 241
Neonatal Screening for Congenital Hypothyroidism Results and Perspectives
Delange, F. (1997) · Hormone Research · doi:10.1159/000185485 · Cited by 221
Tetranucleotide repeat polymorphism at the human c-fes/fps proto-oncogene (FES)
Polymeropoulos, M. H., Rath, D. S., Xiao, H., & Merril, C. R. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.14.4018 · Cited by 215
The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses
Chambers, C. A., Krummel, M. E., Boitel, B., Hurwitz, A., Sullivan, T. J., Fournier, S., Cassell, D., Brunner, M., & Allison, J. P. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00919.x · Cited by 211
Oosterwegel, M. A., Greenwald, R. J., Mandelbrot, D. A., Lorsbach, R. B., & Sharpe, A. H. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80047-8 · Cited by 208
Fallarino, F., Fields, P. E., & Gajewski, T. F. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.1.205 · Cited by 186
Lin, H., Rathmell, J. C., Gray, G. S., Thompson, C. B., Leiden, J. M., & Alegre, M.-L. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.1.199 · Cited by 182
Self-citationRevilla, C., Amsen, D., & Kruisbeek, A. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1645 · Cited by 166
CTLA4 promoter and exon 1 dimorphisms in multiple sclerosiso
Flinstad Harbo, H., Gulowsen Celius, E., Vartdal, F., & Spurkland, A. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.530112.x · Cited by 160
HLA Associations with Hashimoto's thyroiditis
Tendon, N., Zhang, L., & Weetman, A. P. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb00309.x · Cited by 148
Awata, T., Kurihara, S., Iitaka, M., et al. (1998) · Diabetes · doi:10.2337/diab.47.1.128 · Cited by 144
CTLA‐4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis
Braun, J., Donner, H., Siegmund, T., Walfish, P. G., Usadel, K. H., & Badenhoop, K. W. J. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb02993.x · Cited by 137
CTLA4 Gene Polymorphism Confers Susceptibility to Graves' Disease in Japanese
Yanagawa, T., Taniyama, M., Enomoto, S., Gomi, K., Maruyama, H., Ban, Y., & Saruta, T. (1997) · Thyroid · doi:10.1089/thy.1997.7.843 · Cited by 136
Colucci, F., Bergman, M., Penha‐Gonçalves, C., Cilio, C., & Holmberg, D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8670 · Cited by 132
Fas-independent death of activated CD4 + T lymphocytes induced by CTLA-4 crosslinking
Scheipers, P., & Reiser, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10083 · Cited by 121
AUWERA, B. J. V. D., VANDEWALLE, C. L., SCHUIT, F. C., WINNOCK, F., LEEUW, I. H. D., IMSCHOOT, S. V., LAMBERIGTS, G., GORUS, F. K., & the Belgian Diabetes Registry (1997) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1997.t01-1-512-ce1410.x · Cited by 113
Genetic Susceptibility to the Development of Autoimmune Disease
Heward, J. M., & Gough, S. C. L. (1997) · Clinical Science · doi:10.1042/cs0930479 · Cited by 111
GRAVES' DISEASE AND HLA: CLINICAL AND EPIDEMIOLOGIC ASSOCIATIONS
Farid, N. R., STONE, E., & Johnson, G. J. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03421.x · Cited by 109
Linsley, P. S. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.2.289 · Cited by 106
Costimulation and autoimmunity
Tivol, E. A., Schweitzer, A. N., & Sharpe, A. H. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80011-2 · Cited by 101
Damle, N. K., Klussman, K., Leytze, G., Myrdal, S. E., Aruffo, A. A., Ledbetter, J. A., & Linsley, P. S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.6.2686 · Cited by 87
Finn, P. W., He, H., Wang, Y., Wang, Z., Guan, G., Listman, J. A., & Perkins, D. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.9.4074 · Cited by 85
Positive and Negative Regulation of Human T Cell Activation Mediated by the CTLA-4/CD28 Ligand CD80
Boulougouris, G., McLeod, J., Patel, Y. I., Ellwood, C. N., Walker, L. S. K., & Sansom, D. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.3919 · Cited by 36
Neonatal screening for congenital hypothyroidism: results and perspectives. Hormone research
Delange, F. (2000) · Problems of Endocrinology · doi:10.14341/probl11835 · Cited by 15
Cited by
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,042
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
Prabhakar, B. S., Bahn, R. S., & Smith, T. J. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0020 · Cited by 489
Tomer, Y., & Davies, T. F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0030 · Cited by 422
Metadata
- Authors
- Kouki, T., Sawai, Y., Gardine, C. A., Fisfalen, M.-E., Alegre, M.-L., & DeGroot, L. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12-01
- Volume
- 165
- Issue
- 11
- Pages
- 6606-6611
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2149363036
- Cited by
- 505
- References
- 37
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.